Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Non Operating Income for 7 consecutive years, with $13.1 million as the latest value for Q4 2023.

  • Quarterly Non Operating Income rose 97.13% to $13.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Dec 2023, up 248.62% year-over-year, with the annual reading at $51.5 million for FY2023, 248.62% up from the prior year.
  • Non Operating Income for Q4 2023 was $13.1 million at Denali Therapeutics, down from $14.4 million in the prior quarter.
  • The five-year high for Non Operating Income was $14.4 million in Q3 2023, with the low at $1.0 million in Q3 2021.
  • Average Non Operating Income over 5 years is $4.8 million, with a median of $3.1 million recorded in 2020.
  • The sharpest move saw Non Operating Income plummeted 61.58% in 2021, then surged 763.38% in 2023.
  • Over 5 years, Non Operating Income stood at $3.8 million in 2019, then tumbled by 56.9% to $1.6 million in 2020, then decreased by 21.17% to $1.3 million in 2021, then surged by 418.29% to $6.7 million in 2022, then surged by 97.13% to $13.1 million in 2023.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $13.1 million, $14.4 million, and $12.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.